Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN.PACT SFA randomized Trial

Gunnar Tepe, John Laird, Peter Schneider, Marianne Brodmann, Prakash Krishnan, Antonio Micari, Christopher Metzger, Dierk Scheinert, Thomas Zeller, David J. Cohen, David B. Snead, Beaux Alexander, Mario Landini, Michael R. Jaff

Research output: Contribution to journalArticle

282 Citations (Scopus)

Abstract

Background: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease. Methods and Results: The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94±4.89 and 8.81±5.12 cm (P=0.82) and 25.8% and 19.5% (P=0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm (P<0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [P=0.10]). There were no device- or procedurerelated deaths and no major amputations. Conclusions: In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique Identifiers: NCT01175850 and

Original languageEnglish (US)
Pages (from-to)495-502
Number of pages8
JournalCirculation
Volume131
Issue number5
DOIs
StatePublished - Feb 3 2015

Fingerprint

Popliteal Artery
Peripheral Arterial Disease
Thigh
Angioplasty
Pharmaceutical Preparations
Therapeutics
Intermittent Claudication
Femoral Artery
Paclitaxel
Amputation
Multicenter Studies
Thrombosis
Clinical Trials
Safety
Pain
Equipment and Supplies

Keywords

  • Drug-eluting balloons
  • Peripheral arterial disease
  • Peripheral vascular diseases

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN.PACT SFA randomized Trial. / Tepe, Gunnar; Laird, John; Schneider, Peter; Brodmann, Marianne; Krishnan, Prakash; Micari, Antonio; Metzger, Christopher; Scheinert, Dierk; Zeller, Thomas; Cohen, David J.; Snead, David B.; Alexander, Beaux; Landini, Mario; Jaff, Michael R.

In: Circulation, Vol. 131, No. 5, 03.02.2015, p. 495-502.

Research output: Contribution to journalArticle

Tepe, G, Laird, J, Schneider, P, Brodmann, M, Krishnan, P, Micari, A, Metzger, C, Scheinert, D, Zeller, T, Cohen, DJ, Snead, DB, Alexander, B, Landini, M & Jaff, MR 2015, 'Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN.PACT SFA randomized Trial', Circulation, vol. 131, no. 5, pp. 495-502. https://doi.org/10.1161/CIRCULATIONAHA.114.011004
Tepe, Gunnar ; Laird, John ; Schneider, Peter ; Brodmann, Marianne ; Krishnan, Prakash ; Micari, Antonio ; Metzger, Christopher ; Scheinert, Dierk ; Zeller, Thomas ; Cohen, David J. ; Snead, David B. ; Alexander, Beaux ; Landini, Mario ; Jaff, Michael R. / Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN.PACT SFA randomized Trial. In: Circulation. 2015 ; Vol. 131, No. 5. pp. 495-502.
@article{8bbd771558cb4041985409ec8948627e,
title = "Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN.PACT SFA randomized Trial",
abstract = "Background: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease. Methods and Results: The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94±4.89 and 8.81±5.12 cm (P=0.82) and 25.8{\%} and 19.5{\%} (P=0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2{\%} versus 52.4{\%}; P<0.001). The rate of clinically driven target lesion revascularization was 2.4{\%} in the DCB arm in comparison with 20.6{\%} in the PTA arm (P<0.001). There was a low rate of vessel thrombosis in both arms (1.4{\%} after DCB and 3.7{\%} after PTA [P=0.10]). There were no device- or procedurerelated deaths and no major amputations. Conclusions: In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique Identifiers: NCT01175850 and",
keywords = "Drug-eluting balloons, Peripheral arterial disease, Peripheral vascular diseases",
author = "Gunnar Tepe and John Laird and Peter Schneider and Marianne Brodmann and Prakash Krishnan and Antonio Micari and Christopher Metzger and Dierk Scheinert and Thomas Zeller and Cohen, {David J.} and Snead, {David B.} and Beaux Alexander and Mario Landini and Jaff, {Michael R.}",
year = "2015",
month = "2",
day = "3",
doi = "10.1161/CIRCULATIONAHA.114.011004",
language = "English (US)",
volume = "131",
pages = "495--502",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN.PACT SFA randomized Trial

AU - Tepe, Gunnar

AU - Laird, John

AU - Schneider, Peter

AU - Brodmann, Marianne

AU - Krishnan, Prakash

AU - Micari, Antonio

AU - Metzger, Christopher

AU - Scheinert, Dierk

AU - Zeller, Thomas

AU - Cohen, David J.

AU - Snead, David B.

AU - Alexander, Beaux

AU - Landini, Mario

AU - Jaff, Michael R.

PY - 2015/2/3

Y1 - 2015/2/3

N2 - Background: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease. Methods and Results: The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94±4.89 and 8.81±5.12 cm (P=0.82) and 25.8% and 19.5% (P=0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm (P<0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [P=0.10]). There were no device- or procedurerelated deaths and no major amputations. Conclusions: In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique Identifiers: NCT01175850 and

AB - Background: Drug-coated balloons (DCBs) have shown promise in improving the outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symptomatic superficial femoral and popliteal artery disease. Methods and Results: The IN.PACT SFA Trial is a prospective, multicenter, single-blinded, randomized trial in which 331 patients with intermittent claudication or ischemic rest pain attributable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:1 ratio to treatment with DCB or PTA. The primary efficacy end point was primary patency, defined as freedom from restenosis or clinically driven target lesion revascularization at 12 months. Baseline characteristics were similar between the 2 groups. Mean lesion length and the percentage of total occlusions for the DCB and PTA arms were 8.94±4.89 and 8.81±5.12 cm (P=0.82) and 25.8% and 19.5% (P=0.22), respectively. DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001). The rate of clinically driven target lesion revascularization was 2.4% in the DCB arm in comparison with 20.6% in the PTA arm (P<0.001). There was a low rate of vessel thrombosis in both arms (1.4% after DCB and 3.7% after PTA [P=0.10]). There were no device- or procedurerelated deaths and no major amputations. Conclusions: In this prospective, multicenter, randomized trial, DCB was superior to PTA and had a favorable safety profile for the treatment of patients with symptomatic femoropopliteal peripheral artery disease. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique Identifiers: NCT01175850 and

KW - Drug-eluting balloons

KW - Peripheral arterial disease

KW - Peripheral vascular diseases

UR - http://www.scopus.com/inward/record.url?scp=84923684095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923684095&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.114.011004

DO - 10.1161/CIRCULATIONAHA.114.011004

M3 - Article

C2 - 25472980

AN - SCOPUS:84923684095

VL - 131

SP - 495

EP - 502

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5

ER -